We found differences after 4.5 years of follow-up in the 6MWT, and in disease duration modeling, its annual progression was estimated to be 7.71 m in the overall HSP group, 9.12 m in the SPG4 subgroup, and 9.74 m in the subgroup with adult-onset disease. The gene discussed is SPAST; the disease is hereditary spastic paraplegia.